Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16

Hepion Pharmaceuticals, Inc.

Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.
Initial term of 3 months; annual base salary $350,000 with $50,000 deferred until equity financing ≥$3M or departure.
Performance bonus eligible at 35% of base salary upon milestones; pro-rated bonus if terminated without cause before term end.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Kaouthar Lbiati

Interim Chief Executive Officer

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2025-06-16
Filed: June 9, 2025, 7:59 PM ET

On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kaouthar Lbiati was appointed as Interim Chief Executive Officer at Hepion Pharmaceuticals, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.

View on SEC.gov

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-014320

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.